Onconetix (ONCO) Competitors $2.84 +0.17 (+6.37%) Closing price 04:00 PM EasternExtended Trading$2.83 -0.01 (-0.35%) As of 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ONCO vs. INAB, HCWB, APLM, PPBT, LIAN, GTBP, VYNE, THAR, BCTX, and SPRBShould you be buying Onconetix stock or one of its competitors? The main competitors of Onconetix include IN8bio (INAB), HCW Biologics (HCWB), Apollomics (APLM), Purple Biotech (PPBT), LianBio (LIAN), GT Biopharma (GTBP), VYNE Therapeutics (VYNE), Tharimmune (THAR), Briacell Therap (BCTX), and Spruce Biosciences (SPRB). These companies are all part of the "pharmaceutical products" industry. Onconetix vs. Its Competitors IN8bio HCW Biologics Apollomics Purple Biotech LianBio GT Biopharma VYNE Therapeutics Tharimmune Briacell Therap Spruce Biosciences IN8bio (NASDAQ:INAB) and Onconetix (NASDAQ:ONCO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership. Do institutionals and insiders hold more shares of INAB or ONCO? 92.1% of IN8bio shares are held by institutional investors. Comparatively, 23.9% of Onconetix shares are held by institutional investors. 15.5% of IN8bio shares are held by company insiders. Comparatively, 3.1% of Onconetix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is INAB or ONCO more profitable? IN8bio has a net margin of 0.00% compared to Onconetix's net margin of -2,913.71%. IN8bio's return on equity of -218.85% beat Onconetix's return on equity.Company Net Margins Return on Equity Return on Assets IN8bioN/A -218.85% -139.59% Onconetix -2,913.71%-514.04%-75.82% Do analysts recommend INAB or ONCO? IN8bio currently has a consensus target price of $180.00, suggesting a potential upside of 7,692.21%. Given IN8bio's stronger consensus rating and higher possible upside, analysts clearly believe IN8bio is more favorable than Onconetix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IN8bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Onconetix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable earnings & valuation, INAB or ONCO? IN8bio has higher earnings, but lower revenue than Onconetix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIN8bioN/AN/A-$30.44M-$13.57-0.17Onconetix$2.52M0.60-$58.69MN/AN/A Which has more risk & volatility, INAB or ONCO? IN8bio has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500. Comparatively, Onconetix has a beta of 3.37, indicating that its stock price is 237% more volatile than the S&P 500. Does the media favor INAB or ONCO? In the previous week, IN8bio had 3 more articles in the media than Onconetix. MarketBeat recorded 3 mentions for IN8bio and 0 mentions for Onconetix. IN8bio's average media sentiment score of 1.00 beat Onconetix's score of 0.00 indicating that IN8bio is being referred to more favorably in the media. Company Overall Sentiment IN8bio Positive Onconetix Neutral SummaryIN8bio beats Onconetix on 10 of the 13 factors compared between the two stocks. Get Onconetix News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ONCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONCO vs. The Competition Export to ExcelMetricOnconetixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.51M$2.98B$5.45B$9.68BDividend YieldN/A2.46%3.99%4.14%P/E RatioN/A17.9230.1125.01Price / Sales0.60178.93379.5578.79Price / CashN/A41.8335.9458.58Price / Book0.257.268.135.68Net Income-$58.69M-$54.43M$3.26B$265.68M7 Day Performance-17.68%-0.01%1.15%2.51%1 Month Performance-40.83%5.13%2.81%1.88%1 Year Performance-99.37%10.24%28.41%24.00% Onconetix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCOOnconetix0.178 of 5 stars$2.84+6.4%N/A-99.4%$1.51M$2.52M0.0012Gap UpINABIN8bio3.9417 of 5 stars$2.15+2.6%$180.00+8,291.6%-89.9%$6.50MN/A-0.1620News CoveragePositive NewsEarnings ReportUpcoming EarningsHCWBHCW Biologics2.8644 of 5 stars$4.47+6.3%$35.00+683.9%-81.2%$6.43M$1.45M-0.1940Upcoming EarningsAPLMApollomics0.0945 of 5 stars$5.72+2.9%N/A-64.3%$6.31MN/A0.0045Negative NewsPPBTPurple Biotech2.4616 of 5 stars$2.24+1.4%$33.00+1,373.2%N/A$5.82MN/A-0.8620News CoverageEarnings ReportUpcoming EarningsLIANLianBioN/A$0.05-2.4%N/A-82.3%$5.73MN/A-0.07110GTBPGT Biopharma2.0177 of 5 stars$1.74-2.5%$11.00+534.0%-18.7%$5.67MN/A-0.308Upcoming EarningsGap UpVYNEVYNE Therapeutics2.5466 of 5 stars$0.37+0.5%$6.25+1,603.0%-77.8%$5.60M$500K-0.3730Upcoming EarningsGap UpHigh Trading VolumeTHARTharimmune3.3062 of 5 stars$1.26-5.0%$17.00+1,244.9%-53.0%$5.33MN/A-0.162Gap DownBCTXBriacell Therap1.6346 of 5 stars$0.77+2.5%$32.00+4,034.4%-92.4%$5.24MN/A-0.098Stock SplitSPRBSpruce Biosciences2.0071 of 5 stars$0.12+2.8%$131.25+106,261.4%-99.6%$5.21M$4.91M-0.1320News CoverageNegative NewsUpcoming EarningsGap Down Related Companies and Tools Related Companies INAB Alternatives HCWB Alternatives APLM Alternatives PPBT Alternatives LIAN Alternatives GTBP Alternatives VYNE Alternatives THAR Alternatives BCTX Alternatives SPRB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONCO) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Onconetix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Onconetix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ONCO Stock Alerts